Chief Development Officer
Andrea Sáez provides a strong scientific background complemented by broad experience in regulatory, biotech and venture capital roles. Previous to joining Agomab she was COO/CSO at Origo Biopharma. She initiated her academic career with a PhD in Immunology at the Pompeu Fabra University followed by a postdoctoral stay at Vall d’Hebron Hospital where she studied and published on the therapeutic benefit of TGF-ß inhibitors in preclinical cancer models. She gained deep understanding of regulatory affairs and drug development in her role as Scientific and Regulatory Affairs Manager at Asphalion, a leading consultancy, after which she became Director of R&D at Pangaea Oncology managing drug discovery projects in alliance with external institutions such as Cancer Research Technologies (UK). Prior to joining Origo Biopharma, Andrea was a Senior Associate at Asabys Partners, supporting a number of biotech investments including the investment in Origo.